Rayego-Mateos S, Rodrigues-Diez RR, Fernandez-Fernandez B, Mora-Fernández C, Marchant V, Donate-Correa J, et al. Targeting inflammation to treat diabetic kidney disease: the road to 2030. Kidney Int. 2023;103(2):282–96.
Oshima M, Toyama T, Haneda M, Furuichi K, Babazono T, Yokoyama H, et al. Estimated glomerular filtration rate decline and risk of end-stage renal disease in type 2 diabetes. PLoS ONE. 2018;13(8):e0201535.
Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: Challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032–45.
Liu M-C, Li J-L, Wang Y-F, Meng Y, Zheng G-M, Cai Z, et al. Association between serum complements and kidney function in patients with diabetic kidney disease. Front Endocrinol (Lausanne). 2023;14:1195966.
Gao X, Hou R, Li X, Qiu X-H, Luo H-H, Liu S-L, et al. The association between leucine and diabetic nephropathy in different gender: A cross-sectional study in Chinese patients with type 2 diabetes. Front Endocrinol (Lausanne). 2020;11:619422.
Giandalia A, Giuffrida AE, Gembillo G, Cucinotta D, Squadrito G, Santoro D et al. Gender differences in diabetic kidney disease: focus on hormonal, genetic and clinical factors. Int J Mol Sci. 2021;22(11).
Greenhill C. Sex differences in diabetic kidney disease explained. Nat Rev Endocrinol. 2024;20(5):256.
Buchanan CE, Mahmoud H, Cox EF, McCulloch T, Prestwich BL, Taal MW, et al. Quantitative assessment of renal structural and functional changes in chronic kidney disease using multi-parametric magnetic resonance imaging. Nephrol Dial Transpl. 2020;35(6):955–64.
Clotet-Freixas S, Zaslaver O, Kotlyar M, Pastrello C, Quaile AT, McEvoy CM, et al. Sex differences in kidney metabolism May reflect sex-dependent outcomes in human diabetic kidney disease. Sci Transl Med. 2024;16(737):eabm2090.
Feigerlová E, Saulnier PJ, Gourdy P, Roussel R, Halimi JM, Gand E, et al. Sex hormone levels are not associated with progression of renal disease in male patients with T2DM. Diabetes Metab. 2017;43(2):140–5.
Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab. 2008;94(3):907–13.
KDIGO. 2024 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117-S314.
Ando H, Isobe S, Amano T, Yamada T, Ohtsubo H, Yuba M, et al. Predictors of worsening renal function after computed tomography coronary angiography: assessed by cystatin C. J Cardiovasc Comput Tomogr. 2012;6(1):31–6.
Kitagawa N, Ushigome E, Kitagawa N, Ushigome H, Yokota I, Nakanishi N, et al. Diabetic nephropathy ameliorated in patients with normal home blood pressure compared to those with isolated high home systolic blood pressure: A 5-year prospective cohort study among patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2022;19(3):14791641221098193.
Jiang W, Wang J, Shen X, Lu W, Wang Y, Li W, et al. Establishment and validation of a risk prediction model for early diabetic kidney disease based on a systematic review and Meta-Analysis of 20 cohorts. Diabetes Care. 2020;43(4):925–33.
Gregorich M, Kammer M, Heinzel A, Böger C, Eckardt K-U, Heerspink HL, et al. Development and validation of a prediction model for future estimated glomerular filtration rate in people with type 2 diabetes and chronic kidney disease. JAMA Netw Open. 2023;6(4):e231870.
Zhao JV, Schooling CM. The role of testosterone in chronic kidney disease and kidney function in men and women: a bi-directional Mendelian randomization study in the UK biobank. BMC Med. 2020;18(1):122.
Dhindsa S, Reddy A, Karam JS, Bilkis S, Chaurasia A, Mehta A, et al. Prevalence of subnormal testosterone concentrations in men with type 2 diabetes and chronic kidney disease. Eur J Endocrinol. 2015;173(3):359–66.
Al Hayek AA, Khader YS, Jafal S, Khawaja N, Robert AA, Ajlouni K. Prevalence of low testosterone levels in men with type 2 diabetes mellitus: a cross-sectional study. J Family Community Med. 2013;20(3):179–86.
Metcalfe PD, Leslie JA, Campbell MT, Meldrum DR, Hile KL, Meldrum KK. Testosterone exacerbates obstructive renal injury by stimulating TNF-alpha production and increasing proapoptotic and profibrotic signaling. Am J Physiol Endocrinol Metab. 2007;294(2):E435–43.
Pan J, Zheng Z, Mao X, Hu D, Wang W, Liao G, et al. Is there a Two-Way risk between decreased testosterone levels and the progression and prognosis of chronic kidney disease? A cohort study based on the National health and nutrition examination survey database. World J Mens Health. 2024;42(2):429–40.
van der Burgh AC, Khan SR, Neggers SJCMM, Hoorn EJ, Chaker L. The role of serum testosterone and dehydroepiandrosterone sulfate in kidney function and clinical outcomes in chronic kidney disease: a systematic review and meta-analysis. Endocr Connect. 2022;11(6).
Khurana KK, Navaneethan SD, Arrigain S, Schold JD, Nally JV, Shoskes DA. Serum testosterone levels and mortality in men with CKD stages 3–4. Am J Kidney Dis. 2014;64(3):367–74.
Yu J, Ravel VA, You AS, Streja E, Rivara MB, Potukuchi PK, et al. Association between testosterone and mortality risk among U.S. Males receiving Dialysis. Am J Nephrol. 2017;46(3):195–203.
Schmidt A, Luger A, Hörl WH. Sexual hormone abnormalities in male patients with renal failure. Nephrol Dial Transpl. 2002;17(3):368–71.
Thirumavalavan N, Wilken NA, Ramasamy R. Hypogonadism and renal failure: an update. Indian J Urol. 2015;31(2):89–93.
Zhang Q, Yang L, Zhou L, Xin X. Nonlinear association of sex hormone-binding Globulin levels and chronic kidney disease, an analysis based on the National health and nutrition examination survey (NHANES) 2013–2016. Ren Fail. 2024;46(2):2409341.
Leśniak K, Rymarz A, Sobol M, Dymus J, Woźniak-Kosek A, Niemczyk S. Testosterone deficiency and nutritional parameters as predictors of All-Cause mortality among male Dialysis patients. Nutrients. 2022;14(21).
Wang C, Zhang W, Wang Y, Wan H, Chen Y, Xia F, et al. Novel associations between sex hormones and diabetic vascular complications in men and postmenopausal women: a cross-sectional study. Cardiovasc Diabetol. 2019;18(1):97.
Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899–906.
Navarro G, Xu W, Jacobson DA, Wicksteed B, Allard C, Zhang G, et al. Extranuclear actions of the androgen receptor enhance Glucose-Stimulated insulin secretion in the male. Cell Metab. 2016;23(5):837–51.
Liu J, Liu Z, Sun W, Luo L, An X, Yu D, et al. Role of sex hormones in diabetic nephropathy. Front Endocrinol (Lausanne). 2023;14:1135530.
Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of Cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the heart and soul study. Circulation. 2007;115(2):173–9.
Trutin I, Bajic Z, Turudic D, Cvitkovic-Roic A, Milosevic D, Cystatin C. Renal resistance index, and kidney injury molecule-1 are potential early predictors of diabetic kidney disease in children with type 1 diabetes. Front Pediatr. 2022;10:962048.
Lamb EJ, Barratt J, Brettell EA, Cockwell P, Dalton RN, Deeks JJ et al. Accuracy of glomerular filtration rate Estimation using creatinine and Cystatin C for identifying and monitoring moderate chronic kidney disease: the eGFR-C study. Health Technol Assess. 2024;28(35).
Kim SS, Song SH, Kim IJ, Jeon YK, Kim BH, Kwak IS, et al. Urinary Cystatin C and tubular proteinuria predict progression of diabetic nephropathy. Diabetes Care. 2013;36(3):656–61.
Mankhey RW, Bhatti F, Maric C. 17beta-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy. Am J Physiol Ren Physiol. 2005;288(2):F399–405.
Gambineri A, Pelusi C. Sex hormones, obesity and type 2 diabetes: is there a link? Endocr Connect. 2019;8(1):R1–9.
Amory JK, Bremner WJ. Regulation of testicular function in men: implications for male hormonal contraceptive development. J Steroid Biochem Mol Biol. 2003;85(2–5):357–61.
Maneesh M, Jayalakshmi H, Singh TA, Chakrabarti A. Impaired hypothalamic-pituitary-gonadal axis function in men with diabetes mellitus. Indian J Clin Biochem. 2006;21(1):165–8.
Rochira V, Zirilli L, Genazzani AD, Balestrieri A, Aranda C, Fabre B, et al. Hypothalamic-pituitary-gonadal axis in two men with aromatase deficiency: evidence that Circulating estrogens are required at the hypothalamic level for the integrity of gonadotropin negative feedback. Eur J Endocrinol. 2006;155(4):513–22.
Costanzo PR, Suárez SM, Scaglia HE, Zylbersztein C, Litwak LE, Knoblovits P. Evaluation of the hypothalamic-pituitary-gonadal axis in eugonadal men with type 2 diabetes mellitus. Andrology. 2014;2(1):117–24.
Cheung KKT, Luk AOY, So WY, Ma RCW, Kong APS, Chow FCC, et al. Testosterone level in men with type 2 diabetes mellitus and related metabolic effects: A review of current evidence. J Diabetes Investig. 2015;6(2):112–23.
Schianca GPC, Fra GP, Brustia F, Bellan M, Pirovano A, Gualerzi A, et al. Testosterone plasma concentration is associated with insulin resistance in male hypertensive patients. Exp Clin Endocrinol Diabetes. 2017;125(3):171–5.